JPH041303B2 - - Google Patents
Info
- Publication number
- JPH041303B2 JPH041303B2 JP57149466A JP14946682A JPH041303B2 JP H041303 B2 JPH041303 B2 JP H041303B2 JP 57149466 A JP57149466 A JP 57149466A JP 14946682 A JP14946682 A JP 14946682A JP H041303 B2 JPH041303 B2 JP H041303B2
- Authority
- JP
- Japan
- Prior art keywords
- filter paper
- blood
- water
- acetone
- hemoglobin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 43
- 239000008280 blood Substances 0.000 claims description 33
- 210000004369 blood Anatomy 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 102000001554 Hemoglobins Human genes 0.000 claims description 17
- 108010054147 Hemoglobins Proteins 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 238000005259 measurement Methods 0.000 claims description 11
- 239000012503 blood component Substances 0.000 claims description 6
- 238000000691 measurement method Methods 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 11
- 238000004925 denaturation Methods 0.000 description 10
- 230000036425 denaturation Effects 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 229930182830 galactose Natural products 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000010828 elution Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 description 2
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 108010014369 galactose dehydrogenase Proteins 0.000 description 2
- 230000006371 metabolic abnormality Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- AKYHKWQPZHDOBW-UHFFFAOYSA-N (5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol Chemical compound OS(O)(=O)=O.C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 AKYHKWQPZHDOBW-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 239000001576 FEMA 2977 Substances 0.000 description 1
- 208000027472 Galactosemias Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000002704 Guthrie test Methods 0.000 description 1
- 108700028608 Histidinemia Proteins 0.000 description 1
- 206010020365 Homocystinuria Diseases 0.000 description 1
- 208000026156 Hypertyrosinemia Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000030162 Maple syrup disease Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000057144 Uridine Diphosphate Glucose Dehydrogenase Human genes 0.000 description 1
- 108010054269 Uridine Diphosphate Glucose Dehydrogenase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- HXXFSFRBOHSIMQ-FPRJBGLDSA-N alpha-D-galactose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H]1O HXXFSFRBOHSIMQ-FPRJBGLDSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 208000006599 histidinemia Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 208000024393 maple syrup urine disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960003110 quinine sulfate Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 201000011296 tyrosinemia Diseases 0.000 description 1
- 238000007693 zone electrophoresis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
本発明は血液成分の測定法に関する。さらに詳
しくは、小児のマススクリーニングなどに使用さ
れる血液濾紙を用いて測定する際に、該血液濾紙
とエーテル:水:アセトン:アルコールから成る
組成物又は塩化メチレン:水:アセトン:アルコ
ールから成る組成物とを接触せしめ、血色素を変
性固定化した血液濾紙を用いることを特徴とする
血液成分の測定法である。本発明法において測定
される血液成分とはグルコース、ガラクトース、
ガラクトース−1−リン酸、ウリジン−ニリン酸
ガラクトース、オルニチン、フエニルアラニン、
ヒスチジン、ロイシン、メチオニン、チロシンな
どの糖、アミノ酸類である。
小児のマススクリーニングにおいては、新生児
の代謝異常を早期に発見するため生後5〜7日目
に足蹠をランセツトで穿刺し、所定の濾紙に血液
を吸収せしめて乾燥した血液濾紙を検査センター
に送り検査する方法、いわゆるガスリー検査が行
なわれている。本検査で測定されるのは前述に
糖、アミノ酸などであるが、これによりガラクト
ース血症、フエニルケトン尿症、ヒスチジン血
症、メープルシロツプ尿症、ホモシスチン尿症、
高チロシン血症などが診断される。本検査法は、
まず、血液濾紙を径3〜10mmのデイスクに打ち抜
き、このデイスクと測定試薬とを反応せしめる
か、又は、細菌抑制検査法(Bacterial
inhibition assay,BIA法と略)により目的物質
が測定される。前者の例としては、例えば、前記
血液濾紙デイスクにガラクトースデヒドロゲナー
ゼとNADを作用せしめ、生じたNADHの蛍光又
は可視吸収を測定するガラクトースの微量定量法
などがある。又、BIA法の例としては、例えば、
フエニルアラニンの測定において、代謝拮抗剤β
−2−チエニルアラニンを含む最少栄養平板培地
に枯草菌芽胞を植菌し、そこへ血液濾紙デイスク
を並べ、該菌の発育帯から半定量する方法などが
ある。以上のような測定においては、使用した血
液濾紙デイスクから血色素などが溶出して、光度
計測定の障害となつたりあるいは発育帯が不明瞭
であつたりした。
上記問題に関する公知技術としては、ギ酸、酢
酸、アセトン、水蒸気などを用いる血色素の変性
固定化法が報告されている(名古屋市衛生研究所
報第25巻、17ページ、1978年、トーホクジヤーナ
ル オブ エキスペリメンタル メデイシン
(Tohoku J.Exp.Med.)第133巻、371ページ、
1981年など)。これら先行技術の不利な点は、変
性固定化操作に長時間要したり、高温処理である
ため被測定物が分解されること又は使用する薬剤
に刺激性があることなどである。さらに、変性固
定化後において、使用した薬剤を除去、乾燥する
ために長時間を要したりあるいは特別な装置を必
要とすることがある。すなわち、ギ酸、酢酸など
使用した場合は濾紙に付着した余分の酸を除去す
るためにデシケーター中で減圧下操作し、さらに
活性炭を存在させることも必要であつた。又、有
機溶媒と水との混合系を使用した場合は、低温で
乾燥させようとすると一晩を要した。本発明者ら
は上記欠点を改善すべく研究中に水:アセトン:
アルコールから成る組成物を用いると操作が簡単
であることを知つたが、まだ長時間を要するなど
の欠点があつた。
本発明は上記知見から生まれたものであつて、
その要旨は、血液濾紙とエーテル:水:アセト
ン:アルコールから成る組成物又は塩化メチレ
ン:水:アセトン:アルコールから成る組成物と
を接触せしめることにより該血液濾紙の血色素を
変性固定化し、血色素の溶出を完全に防止した血
液濾紙を用いる血液成分の測定法である。本発明
法では上記のようにして得た変性固定化血液濾紙
を用いて、公知の方法により血液成分を測定する
ことができる。すなわち、その例示としては次の
方法がある。その第一は、前述のガラクトースの
微量定量法のような測定物質と共役するNAD
(P)又はNAD(P)Hの酸化還元に関する酵素
反応を含む方法である。この方法では反応によつ
て生じた蛍光又は可視吸収の変化を蛍光光度計又
は吸光光度計で測定する。第二は、前述の細菌抑
制検査法を用いる方法である。これらの方法で測
定されるのは前述の糖、アミノ酸などであるが、
本発明の効果は、蛍光又は可視吸収を利用する微
量測定法において、特に、顕著である。
本発明法に使用する血色素の変性固定化試薬は
前述のようにエーテル:水:アセトン:アルコー
ル又は塩化メチレン:水:アセトン:アルコール
から成る組成物である。アルコールはメタノール
又はエタノールのように低沸点のものがよい。変
性固定化に有効な試薬の混合割合は後述のように
広い範囲で選択できる。変性固定化の操作は、例
えば次のように行う事ができる。新生児の先天性
代謝異常児のマススクリーニングに使用されてい
るガスリー紙濾紙(第一化学製)に数滴血液を浸
み込ませ風乾する。このようにして得られた血液
濾紙は1cm径に約20〜30μlの血液を含む。この血
液濾紙から適当の大きさ(通常3mm径)のデイス
クを打ち抜き、これを適当な容器、例えば測定に
用いる試験管に入れ、そこへ前記変性固定化用試
薬を加えて、室温又は37℃位の恒温水槽中で約30
分〜1時間処理する。加える変性固定化用試薬の
量はデイスクに充分浸み込めばよく、3mm径デイ
スク1個の場合は約20μlである。本発明法では上
記時間、すなわち約30分〜1時間で変性固定化と
乾燥が完了するため、別に加熱又は減圧等の乾燥
操作をする必要がない。デイスクが乾燥したら、
そのまま同じ試験管を用いて次の測定操作に移る
こともできる。以上のようにして得られた血液濾
紙デイスクは血色素の溶出が全くなく、反応系へ
の障害もない。又、本発明法により変性固定化の
操作がきわめて迅速、簡単に行うことができるよ
うになつた。変性固定化用試薬の組成を以下に説
明する。すなわち前述の血液濾紙を径3mmのデイ
スクに打ち抜き、これに試験管に入れ、第1表に
示す組成の試薬を20μl加えて血色素の変性固定化
能をみた。変性固定化ならびに乾燥に要する時間
と、得られたデイスクを水に浸し血色素の溶出度
を測定した結果を第1表に示す。同表において、
所要時間は四段階、すなわち+は1時間以内、
は2時間以内、は4時間以内、〓は4時間を越
えるものを表わし、また、血色素の溶出が認めら
れるものを(×)、認められないものを(○)と
表示した。さらに総合評価を行い、Cは変性固定
化に使用可能なもの、Bはより好適なもの、Aは
最も好適なものをそれぞれ表す。
The present invention relates to a method for measuring blood components. More specifically, when measuring using a blood filter paper used for mass screening of children, a composition consisting of the blood filter paper and ether:water:acetone:alcohol or a composition consisting of methylene chloride:water:acetone:alcohol is used. This method of measuring blood components is characterized by using blood filter paper in which hemoglobin has been denatured and fixed by contacting it with an object. Blood components measured in the method of the present invention include glucose, galactose,
Galactose-1-phosphate, uridine-diphosphate galactose, ornithine, phenylalanine,
These are sugars and amino acids such as histidine, leucine, methionine, and tyrosine. In pediatric mass screening, in order to detect metabolic abnormalities in newborns early, the footpad is punctured with a lancet on the 5th to 7th day after birth, blood is absorbed into a designated filter paper, and the dried blood filter paper is sent to a testing center. A method of testing is the so-called Guthrie test. This test measures sugar, amino acids, etc. as mentioned above, which can lead to galactosemia, phenylketonuria, histidinemia, maple syrup urine disease, homocystinuria, etc.
Hypertyrosinemia is diagnosed. This test method is
First, blood filter paper is punched out into disks with a diameter of 3 to 10 mm, and this disk is reacted with the measurement reagent, or the bacterial suppression test method (Bacterial
The target substance is measured by inhibition assay (abbreviated as BIA method). Examples of the former include, for example, a galactose microquantification method in which galactose dehydrogenase and NAD are allowed to act on the blood filter paper disk and the fluorescence or visible absorption of the generated NADH is measured. In addition, examples of the BIA law include, for example:
In the measurement of phenylalanine, antimetabolite β
There is a method in which Bacillus subtilis spores are inoculated into a minimal nutrient plate medium containing -2-thienylalanine, blood filter paper disks are arranged there, and semi-quantification is carried out from the growth zone of the bacteria. In the above measurements, hemoglobin and the like were eluted from the blood filter paper disk used, which interfered with photometer measurements or made the growth zone unclear. As a known technique related to the above problem, a method of denaturing and fixing hemoglobin using formic acid, acetic acid, acetone, water vapor, etc. has been reported (Nagoya City Institute of Health Bulletin Vol. 25, p. 17, 1978, Tohoku Journal of Extract). Perimental Medicine (Tohoku J.Exp.Med.) Volume 133, Page 371,
(e.g. 1981). Disadvantages of these prior art techniques include that the denaturation and fixation operation takes a long time, that the analyte is degraded due to the high temperature treatment, and that the chemicals used are irritating. Furthermore, after denaturation and fixation, it may take a long time or special equipment to remove and dry the used drug. That is, when formic acid, acetic acid, etc. are used, it is necessary to operate under reduced pressure in a desiccator in order to remove excess acid adhering to the filter paper, and it is also necessary to have activated carbon present. Furthermore, when a mixed system of organic solvent and water was used, it took overnight to dry at a low temperature. The present inventors are conducting research to improve the above drawbacks: Water: Acetone:
Although it was found that using a composition made of alcohol was easier to operate, it still had drawbacks such as requiring a long time. The present invention was born from the above knowledge, and
The gist is that the hemoglobin on the blood filter paper is denatured and fixed by contacting the blood filter paper with a composition consisting of ether:water:acetone:alcohol or a composition consisting of methylene chloride:water:acetone:alcohol, and the hemoglobin is eluted. This is a method for measuring blood components using blood filter paper that completely prevents blood loss. In the method of the present invention, blood components can be measured by known methods using the modified fixed blood filter paper obtained as described above. That is, examples include the following method. The first is NAD conjugated to a measuring substance, such as the method for microquantitating galactose mentioned above.
This method involves an enzymatic reaction involving redox of (P) or NAD(P)H. In this method, the change in fluorescence or visible absorption caused by the reaction is measured using a fluorometer or spectrophotometer. The second method is to use the above-mentioned bacterial suppression test method. These methods measure the aforementioned sugars, amino acids, etc.
The effects of the present invention are particularly remarkable in trace measurement methods that utilize fluorescence or visible absorption. As mentioned above, the hemoglobin denaturation fixation reagent used in the method of the present invention is a composition consisting of ether:water:acetone:alcohol or methylene chloride:water:acetone:alcohol. The alcohol preferably has a low boiling point, such as methanol or ethanol. The mixing ratio of reagents effective for denatured immobilization can be selected within a wide range as described below. The denaturation fixation operation can be performed, for example, as follows. A few drops of blood is soaked into a Guthrie paper filter (manufactured by Daiichi Chemical), which is used for mass screening of newborns with congenital metabolic abnormalities, and air-dried. The blood filter paper thus obtained contains approximately 20-30 μl of blood per 1 cm diameter. Cut out a disk of an appropriate size (usually 3 mm diameter) from this blood filter paper, place it in a suitable container, such as a test tube used for measurement, add the denatured fixation reagent there, and let it cool at room temperature or around 37°C. Approximately 30 minutes in a constant temperature water tank
Process for minutes to 1 hour. The amount of denatured fixation reagent to be added is sufficient to soak into the disk, and is approximately 20 μl for one 3 mm diameter disk. In the method of the present invention, denatured fixation and drying are completed in the above-mentioned time, that is, about 30 minutes to 1 hour, so there is no need to perform a separate drying operation such as heating or reduced pressure. Once the disk is dry,
You can also move on to the next measurement operation using the same test tube. The blood filter paper disk obtained as described above does not elute hemoglobin at all and does not cause any hindrance to the reaction system. Furthermore, the method of the present invention has made it possible to carry out denaturation and immobilization very quickly and easily. The composition of the reagent for denaturation and immobilization will be explained below. That is, the aforementioned blood filter paper was punched out into a disk with a diameter of 3 mm, placed in a test tube, and 20 μl of a reagent having the composition shown in Table 1 was added to examine the ability to denature and fix hemoglobin. Table 1 shows the time required for denaturation fixation and drying, and the results of measuring the degree of elution of hemoglobin by soaking the obtained disk in water. In the same table,
There are four levels of time required: + means less than 1 hour;
indicates within 2 hours, within 4 hours, 〓 indicates over 4 hours, and cases where hemoglobin elution was observed were indicated as (x), and cases where no hemoglobin was observed were indicated as (○). Furthermore, comprehensive evaluation was performed, and C represents one that can be used for denaturation and immobilization, B represents a more suitable one, and A represents a most suitable one.
【表】【table】
【表】
第1表に示す結果からわかるように、変性固定
化に適する試薬組成はエーテル:水:アセトン:
メタノールの比が
20〜83:3〜32:2〜48:3〜48であり、好適に
は
20〜83:3〜16:2〜48:7〜40の割合である。
第2表には塩化メチレン:水:アセトン:メタ
ノールの系の場合を示す。表の記述の仕方は第1
表と同じである。[Table] As can be seen from the results shown in Table 1, the reagent composition suitable for denatured immobilization is ether: water: acetone:
The ratio of methanol is 20-83:3-32:2-48:3-48, preferably 20-83:3-16:2-48:7-40. Table 2 shows the case of methylene chloride:water:acetone:methanol system. How to write a table is the first
Same as table.
【表】
第2表に示す結果からわかるように、塩化メチ
レン:水:アセトン:メタノールの場合、適する
のは25〜83:3〜20:2〜30:2〜45であり、好
適には50〜83:3〜10:2〜30:2〜30の割合で
ある。
本発明法は以上述べた以外にも濾紙クロマトグ
ラフイー、薄層クロマトグラフイー、澱粉ゾーン
電気泳動などにおけるテイリングの防止又はガス
クロマトグラフイー、液体クロマトグラフイーな
どの充填剤の目詰まりの防止にも有用である。
試験例 1.
ガスリー氏口紙(第1化学製)に血液を数滴浸
み込ませ、風乾して血液濾紙を得た。これを径3
mmのデイスクに打ち抜き、1個ずつ試験管に入
れ、さらに第3表に示す組成の変性固定化試薬
20μlを加えて、室温に1時間放置した。
得られた血液濾紙デイスクの血色素が完全に固
定化されているか調べるために、試験管に水を入
れ血色素の溶出をみた。すなわち変性固定化血液
デイスクの水溶出液の蛍光強度を励起波長
381nm,蛍光波長382nmで測定した。標準液は
0・29μM硫酸キニーネ(蛍光強度0・1)及び
対照液は水(同じく0)を用いた。結果を第3表
に示す。同表からわかるように本発明法により変
性固定化された血液デイスクからは血色素の溶出
が全く認められなかつた。[Table] As can be seen from the results shown in Table 2, in the case of methylene chloride:water:acetone:methanol, the suitable ratio is 25 to 83:3 to 20:2 to 30:2 to 45, and preferably 50 The ratio is ~83:3~10:2~30:2~30. In addition to the above-mentioned methods, the method of the present invention can also be used to prevent tailing in filter paper chromatography, thin layer chromatography, starch zone electrophoresis, etc., and to prevent clogging of packing materials in gas chromatography, liquid chromatography, etc. Useful. Test Example 1. Several drops of blood were impregnated into Guthrie filter paper (manufactured by Daiichi Kagaku) and air-dried to obtain blood filter paper. This is diameter 3
Punch out 1 mm disks, place them one by one in a test tube, and add denatured immobilization reagent with the composition shown in Table 3.
20 μl was added and left at room temperature for 1 hour. In order to check whether the hemoglobin in the obtained blood filter paper disk was completely immobilized, water was placed in a test tube and the elution of the hemoglobin was observed. i.e., the fluorescence intensity of the aqueous eluate of the denatured fixed blood disk is determined by the excitation wavelength.
The measurement was performed at 381 nm and the fluorescence wavelength was 382 nm. The standard solution used was 0.29 μM quinine sulfate (fluorescence intensity 0.1), and the control solution used water (also 0). The results are shown in Table 3. As can be seen from the table, no elution of hemoglobin was observed from the blood disks denatured and fixed by the method of the present invention.
【表】
実施例 1.
ガラクトースの測定
既知量のガラクトースを含む各種血液サンプル
を前述ガスリー氏濾紙に浸み込ませ、風乾したの
ち、3mm径に打ち抜いて血液濾紙デイスクを得
た。該デイスクを1個ずつ試験管に入れ、そこへ
エーテル:水:アセトン:メタノールの比が50:
10:10:30の組成物20μlを加え、室温で1時間放
置し血色素の変性固定化処理を行つた。その後試
験管に13mM NDA,5×10-2mg/mlのガラクト
ース脱水素酵素(ベーリンガーマンハイ社製)、
1M−トリス塩酸緩衝液(ph8・0)を各々10μl加
え、37℃で1時間反応させた。水3mlを加え、生
成したNADHの蛍光を励起波長340nm,蛍光波
長450nmで測定した。結果は第1図に示すよう
に、ガラクトース濃度と蛍光強度の間にはよい直
線性が得られた。
実施例 2.
ウリジン−ニリン酸(UDP)ガラクトースの
測定
ガスリー紙濾紙に血液サンプルを浸み込ませ風
乾したのち、3mm径に打ち抜いて血液濾紙デイス
クを得た。該デイスクを試験管に入れ、そこへ塩
化メチレン:水:アセトン:メタノールの比が
70:10:5:15の組成物20μlを加え、室温で1時
間放置して血色素の変性固定化処理を行つた。そ
の後試験管に13mM NDA,0・2u/mlのUDP
ガラクトース−4−エピメラーゼ(シグマ社製)、
0・03u/mlのUDPグルコース脱水素酵素(ベー
リンガーマンハイム社製)、1M−トリス塩酸緩衝
液(ph8・0)を各々10μl加え37℃、1時間反応
させた。以下実施例1.と同様にして、生成した
NADHの蛍光を測定し、検量線からUDPガラク
トース量を求めた。その結果本血液サンプル中の
濃度は0・1mMであつた。[Table] Example 1. Measurement of galactose Various blood samples containing a known amount of galactose were impregnated into the aforementioned Guthrie filter paper, air-dried, and then punched out to a diameter of 3 mm to obtain a blood filter paper disk. Place the disks one by one in a test tube and add ether:water:acetone:methanol in a ratio of 50:
20 μl of a 10:10:30 composition was added and left at room temperature for 1 hour to perform denaturation and fixation treatment of hemoglobin. Then, in a test tube, add 13mM NDA, 5 x 10 -2 mg/ml galactose dehydrogenase (Boehringer Mann High),
10 μl of 1M Tris-HCl buffer (pH 8.0) was added to each, and the mixture was reacted at 37° C. for 1 hour. 3 ml of water was added, and the fluorescence of the generated NADH was measured at an excitation wavelength of 340 nm and a fluorescence wavelength of 450 nm. As shown in FIG. 1, good linearity was obtained between the galactose concentration and the fluorescence intensity. Example 2. Measurement of uridine-diphosphoric acid (UDP) galactose A blood sample was impregnated into a Guthrie paper filter, air-dried, and then punched out to a diameter of 3 mm to obtain a blood filter paper disk. Place the disk in a test tube and add the ratio of methylene chloride:water:acetone:methanol.
20 μl of a 70:10:5:15 composition was added and left at room temperature for 1 hour to perform denaturation and fixation treatment of hemoglobin. Then add 13mM NDA and 0.2u/ml UDP to the test tube.
Galactose-4-epimerase (manufactured by Sigma),
10 μl each of 0.03 u/ml UDP glucose dehydrogenase (manufactured by Boehringer Mannheim) and 1M Tris-HCl buffer (ph 8.0) were added and reacted at 37° C. for 1 hour. The following was generated in the same manner as in Example 1.
The fluorescence of NADH was measured, and the amount of UDP galactose was determined from the calibration curve. As a result, the concentration in this blood sample was 0.1mM.
第1図は本発明法によるガラクトースの測定に
おけるガラクトース濃度と蛍光強度の関係を表わ
す図である。
FIG. 1 is a diagram showing the relationship between galactose concentration and fluorescence intensity in the measurement of galactose by the method of the present invention.
Claims (1)
水:アセトン:アルコールから成る組成物又は塩
化メチレン:水:アセトン:アルコールから成る
組成物の作用により該血液濾紙に含まれる血色素
を変性固定化せしめた血液濾紙を用いることを特
徴とする血液成分の測定法。1 Ether in measurements using blood filter paper:
A method for obtaining blood components characterized by using a blood filter paper in which hemoglobin contained in the blood filter paper has been denatured and fixed by the action of a composition consisting of water:acetone:alcohol or a composition consisting of methylene chloride:water:acetone:alcohol. Measurement method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57149466A JPS5938654A (en) | 1982-08-28 | 1982-08-28 | Measurement of blood component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57149466A JPS5938654A (en) | 1982-08-28 | 1982-08-28 | Measurement of blood component |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5938654A JPS5938654A (en) | 1984-03-02 |
| JPH041303B2 true JPH041303B2 (en) | 1992-01-10 |
Family
ID=15475748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57149466A Granted JPS5938654A (en) | 1982-08-28 | 1982-08-28 | Measurement of blood component |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5938654A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5845639A (en) * | 1981-09-12 | 1983-03-16 | Victor Co Of Japan Ltd | Manufacture for reproducing stylus detecting change in static capacitance value |
| JPS6463868A (en) * | 1988-07-23 | 1989-03-09 | Kurasutaa Koa Kk | Detection of hepatitis virus due to dried blood on filter paper |
-
1982
- 1982-08-28 JP JP57149466A patent/JPS5938654A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5938654A (en) | 1984-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sokol et al. | Immobilized-enzyme rate-determination method for glucose analysis. | |
| EP0261591B1 (en) | Method for assaying 1,5-anhydroglucitol and kit therefor | |
| Hyland et al. | Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology | |
| FI97551B (en) | Method of analysis, reagent composition and its use for the determination of glucose | |
| Young et al. | Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution–electrospray ionization tandem mass spectrometry | |
| Chatterjee et al. | Electrochemical determination of methylglyoxal as a biomarker in humanplasma | |
| Soldatkina et al. | A novel amperometric glutamate biosensor based on glutamate oxidase adsorbed on silicalite | |
| US5204267A (en) | Method of glucose stabilization and analysis in dried blood spot samples | |
| Sakuragawa et al. | Fluorometric determination of microamounts of hydrogen peroxide with an immobilized enzyme prepared by coupling horseradish peroxidase to chitosan beads | |
| Hlavay et al. | Fibre-optic biosensor for hypoxanthine and xanthine based on a chemiluminescence reaction | |
| Hayashi et al. | High-performance liquid chromatographic determination of α-keto acids in plasma with fluorometric detection | |
| JP3217066B2 (en) | Compositions useful for anaerobic determination of analytes | |
| JPH041303B2 (en) | ||
| US3645692A (en) | Process for the preparation, preservation and transportation of blood and serum samples for use in clinical analyses | |
| CH644455A5 (en) | PROCESS FOR QUANTITATIVE ANALYSIS OF CYCLIC NUCLEOTIDES AND A SET OF REAGENTS FOR THE IMPLEMENTATION OF THIS PROCESS. | |
| Trojanowicz et al. | Biosensing in high-performance chemical separations | |
| Aigner et al. | Amperometric biosensor for total monoamines using a glassy carbon paste electrode modified with human monoamine oxidase B and manganese dioxide particles | |
| Tsiafoulis et al. | Development of an amperometric biosensing method for the determination of L-fucose in pretreated urine | |
| Chaichi et al. | Glucose chemiluminescence biosensor based on covalent immobilization of enzyme in glutaraldehyde-functionalized glass cell and direct coupling of chitosan-induced Au/Ag alloy nanoparticles | |
| JP2642527B2 (en) | Catalase activity measurement method | |
| JP2665673B2 (en) | Method for measuring 1,5-anhydroglucitol in a sample containing glucose | |
| KR970001814B1 (en) | Process for measuring the content of component in vital fluid | |
| JP4544598B2 (en) | Liquid reagent and storage method | |
| JPH0870893A (en) | Diagnosis of dog diabetes, determination of 1,5-anhydroglucitol and kit therefor | |
| JPS60210998A (en) | Test composition, test kit and method for enzymatical measurement of inorganic phosphate |